Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages 336-344

  Svicher, Valentina ^a   Alteri, Claudia ^a   Artese, Anna ^b   Forbici, Federica ^c   Santoro, Maria Mercedes ^a   Schols, Dominique ^d   Van Laethem, Kristel ^d   Alcaro, Stefano ^a   Costa, Giosuè ^a   Tommasi, Chiara ^c   Zaccarelli, Mauro ^c   Narciso, Pasquale ^c   Antinori, Andrea ^c   Ceccherini Silberstein, Francesca ^a   Balzarini, Jan ^d   Perno, Carlo Federico ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

docking analysis; drug resistance; emtricitabine; HIV 1; in vitro selection experiment; lamivudine; RT; structural analysis; tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE; POL PROTEIN; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; VIRUS REPLICATION; ADAPTATION; AMINO ACID SUBSTITUTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; VIROLOGY;

ADAPTATION, BIOLOGICAL; ADENINE; ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHONIC ACIDS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; ORGANOPHOSPHONATES;

EID: 78049236987     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e6763f     Document Type: Article

References (40)

1. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3:e356.
2. Kozal MJ, Hullsiek KH, Macarthur RD, et al, and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-näve participants started on three different antiretroviral therapy strategies. HIV Clin Trials. 2007;8:357-370.
3. Zaccarelli M, Tozzi V, Lorenzini P, et al, and Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS. 2005;19:1081-1089.
4. Zaccarelli M, Tozzi V, Lorenzini P, et al. The V118I mutation as a marker of advanced HIV infection and disease progression. Antivir Ther. 2007;12: 163-168.
5. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537.
6. Walmsley S, Bernstein B, King M, et al, and M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
7. Gupta SK, Rosenkranz SL, Cramer YS, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22:1919-1927.
8. Margot NA, Enejosa J, Cheng AK, et al, and Study 934 Team. Development of HIV-1 drug resistance through 144 weeks in antire-troviral-näve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr. 2009;52:209-221.
9. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel; International AIDS Society-USA. JAMA. 2008;300:555-570.
10. Schinazi RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37:875-881.
11. Tisdale M, Kemp SD, Parry NR, et al. Rapid in-vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci \USA. 1993;90:5653-5656.
12. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
13. Kavlick MF, Shirasaka T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2',3'-dideoxy-3'- thiacytidine. Antiviral Res. 1995;28:133-146.
14. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
15. Ceccherini-Silberstein F, Erba F, Gago F, et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS. 2004;18:F11-F19.
16. Balzarini J, Cahard D, Wedgwood O, et al. Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleo-side analogues against visna virus infection. J AIDS. 1998;17:296-302.
17. Snoeck J, Riva C, Steegen K, et al. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005;128:47-53.
18. HIV Drug Resistance Database. Available at: http://www.hivdbstanford. edu. Accessed June 2009.
19. Protein Data Bank. Available at: http://www.rcsb.org/PDB. Accessed June 2009.
20. Huang H, Chopra R, Verdine GL, et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 1998;282:1669-1675.
21. McDonald DQ, Still WC. AMBER torsional parameters for the peptide backbone. Tetrahedron Lett. 1992;33:7743-7746.
22. Still WC, Tempczyk A, Hawley RC, et al. Semianalytical treatment of solvation for molecular mechanism and dynamics. J Am Chem Soc. 1990; 112:6127-6129.
23. Mohamadi F, Richards NGJ, Guida WC. MacroModel: an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem. 1990;11:440-467.
24. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free-energy function. J Comput Chem. 1998;19:1639-1662.
25. DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific; 2002. Available at: http://www.pymol.org.
26. Balzarini J, Holy A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in-vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother. 1993;37:332-338.
27. Coleman RS, Woodward RL, Hayes AM, et al. Dependence of DNA sequence selectivity and cell cytotoxicity on azinomycin A and B epoxyamide stereochemistry. Org Lett. 2007;9:1891-1894.
28. Maserati R, De Silvestri A, Uglietti A, et al, and ARCA Study Group. Emerging mutations at failure of HAART containing lamivudine/ tenofovir or emtricitabine/tenofovir: The ARV Resistance Cohort Analysis Database. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2009; Montreal, Canada. Abstract 644.
29. Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis. 2006;42:126-131.
30. Feng JY, Shi J, Schinazi RF, et al. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. F A S E B J. 1999;13:1511-1517.
31. Cammack N, Rouse P, Marr CL, et al. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem Pharmacol. 1992;43:2059-2064.
32. Wang LH, Begley J, St. Claire RL III, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20:1173-1182.
33. Bousquet L, Pruvost A, Didier N, et al. Emtricitabine: inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci. 2008;35:247-256.
34. Stone C, Ait-Khaled M, Craig C, et al. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother. 2004;48:1413-1415.
35. Murry JP, Higgins J, Matthews TB, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol. 2003;77:1120-1130.
36. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. 1999;4:87-94.
37. Borroto-Esoda K, Vela JE, Myrick F, et al. In-vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377-384.
38. Feng JY, Ly JK, Myrick F, et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in-vitro: a mechanism of action study. Retrovirology. 2009;6:44.
39. Sato H, Tomita Y, Ebisawa K, et al. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01-AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J Virol. 2001;75:5604-5613.
40. Emerging Mutations at Failure of HAART Containing Lamivudine/ Tenofovir or Emtricitabine/Tenofovir: The ARV Resistance Cohort Analysis Database. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol. 2009;83:2029-2033.